还原性谷胱甘肽联合核苷类似物治疗乙肝肝硬化的效果

Effect of reduced glutathione combined with nucleoside analogues in the treatment of hepatitis B and liver cirrhosis

目的研究分析还原性谷胱甘肽联合核苷类似物治疗乙肝肝硬化的效果与使用价值。方法 150例乙肝肝硬化患者,采用随机分组法将患者分为实验组与对照组,各75例。对照组患者采用核苷类似物进行抗病毒治疗,实验组患者在对照组基础上采用还原性谷胱甘肽。对比两组患者肝功能各项指标[谷酰转肽酶(GGT)、天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)]、并发症发生情况。结果实验组患者GGT水平为(75.21±18.34)U/L、AST水平为(55.56±14.77)U/L、ALT水平为(49.26±18.77)U/L,均优于对照组的(28.56±10.11)、(36.13±9.25)、(17.12±8.12)U/L,差异具有统计学意义(P<0.05)。实验组并发症发生率为6.67%(5/75)与对照组的6.67%(5/75)对比,差异无统计学意义(P>0.05)。结论乙肝肝硬化持续发展导致肝功能损伤,采用还原性谷胱甘肽能够有效提高治疗有效率,改善患者的肝功能情况,有效缓解患者肝脏纤维化进程,生存质量得以明显提高。除此之外药物的使用并没有导致不良反应的明显增加,使用安全性较高,值得在临床治疗中进行推广使用。

Objective To study and analyze the effect and value of reduced glutathione combined with nucleoside analogues in the treatment of hepatitis B and liver cirrhosis. Methods A total of 150 patients with hepatitis B and liver cirrhosis were randomly divided into experimental group and control group, with 75 cases in each group. Patients in the control group were treated with nucleoside analogues for antiviral treatment, while patients in the experimental group were treated with reduced glutathione on the basis of the control group. The liver function indexes [glutamyl transpeptidase(GGT), aspartate aminotransferase(AST), alanine aminotransferase(ALT)] and the occurrence of complications were compared between the two groups. Results GGT(75.21± 18.34) U/L, AST(55.56±14.77) U/L and ALT(49.26±18.77) U/L of the experimental group were all better than(28.56±10.11),(36.13±9.25) and(17.12±8.12) U/L of the control group, and the difference was statistically significant(P<0.05). The incidence of complications of the experimental group was 6.67%(5/75), which had no statistically significant difference compared with 6.67%(5/75) of the control group(P>0.05). Conclusion Reduced glutathione can effectively improve the treatment efficiency of patients with hepatitis B liver cirrhosis, improve the patient’s liver function, and effectively alleviate the patient’s liver fibrosis process, and improve the quality of life without increasing adverse reactions. It is safe, and worthy of clinical promotion and application.